Japanese study of Linagliptin for type 2 diabetes patients with NAFLD in Kagoshima
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Linagliptin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms J-LINK
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.
- 03 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2014 New trial record